Heart failure with preserved ejection fraction (HFpEF) is a complex and multifactorial heart disease that traditionally has had no effective therapy options beyond congestive symptom’s control [1]. The irruption of sodium−glucose cotransporter 2 inhibitors (SGLT-2i) empagliflozin and dapagliflozin substantially modified its management, incorporating for first time effective drugs that reduced the primary composite endpoint of cardiovascular death and hospitalization for heart failure (HF) in patients with HFpEF and HF mildly reduced ejection fraction (HFmrEF).
